Boada, A. http://orcid.org/0000-0001-9809-5308
Carrera, C. http://orcid.org/0000-0003-1608-8820
Segura, S. http://orcid.org/0000-0003-0653-1382
Collgros, H. http://orcid.org/0000-0002-1475-0668
Pasquali, P. http://orcid.org/0000-0003-1504-0665
Bodet, D. http://orcid.org/0000-0003-2227-0696
Puig, S. http://orcid.org/0000-0003-1337-9745
Malvehy, J. http://orcid.org/0000-0002-6998-914X
Article History
Received: 20 March 2018
Accepted: 9 May 2018
First Online: 24 May 2018
Compliance with ethical standards
:
: Dr. Aram Boada has received speaker honorarium from Roche, Novartis, and BMS. Dr. Susana Puig has been consultant of Amgen, ISDIN, La Roche Posay, Leo Pharma, Almirall, Piere Fabre, BMS, and has received research grants from Leo Pharma, Almirall, and Novartis. Dr. Josep Malvehy has been consultant of Amgen, Novartis, BMS, Glaxo, Piere Fabre, Merk, MSD, Sanofi, Sunpharma, Incyte, Almirall, Leo Pharma, ISDIN, and has received research grants from Amgen, Novartis, Roche, BMS, Glaxo, Pierre Fabre, Merk, MSD, Sanofi, Sunpharma, Incyte, Almirall, and Leo Pharma. The remaining authors have no conflict of interest to declare.
: The manuscript does not contain clinical studies or patient data.
: Informed consent was obtained from all individual for whom identifying pictures are included in this article.